Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Patricia Tarilonte"'
Autor:
Lucía Galán Dávila, Fernando Martinez Valle, Juan Buades Reinés, Juan Gonzalez-Moreno, Inés Losada López, Teresa Sevilla, Francisco Muñoz Beamud, José Eulalio Bárcena Llona, Manuel Romero Acebal, Francesca Setaro, Diana Primiano, Patricia Tarilonte
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Variant transthyretin amyloidosis (ATTRv) is a rare multisystemic disorder caused by mutations in the transthyretin (TTR) gene. The aim of the present work was to describe the clinical profile of asymptomatic carriers (AC) and Cou
Externí odkaz:
https://doaj.org/article/7af854a35a024965ae84da2f60cdfa1e
Autor:
Maria Dolores Santos-Rubio, Paul Lebeau, D. Tran, Patricia Tarilonte, Pablo Mallaina, Lucía Galán, José Manuel Martínez-Sesmero, Francisco Muñoz-Beamud, Mark H. Rozenbaum, Michelle Stewart, Juan Gonzalez-Moreno, C. Peral
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 21(5)
Background: Transthyretin amyloid polyneuropathy (ATTR-PN) is a fatal disease associated with substantial burden of illness. Three therapies are approved by the European Medicines Agency for the management of this rare disease. The aim of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64abe4e224e0a603594fca1e85fa8966
https://pubmed.ncbi.nlm.nih.gov/33724140
https://pubmed.ncbi.nlm.nih.gov/33724140
Autor:
Marco Paz, Alejandro De la Sierra, Marc Saez, Maria Antonia Barceló-Radó, Juan J Rodriguez, Pilar Vera, Cristina Lagarón, Patricia Tarilonte, Jose M Garrido, Gabriel Coll de Tuero
Publikováno v:
Hypertension. 64
Background and aim: The use of antihypertensive drugs should be based on the knowledge of their blood pressure (BP)-lowering effect . Most of the clinical trials only assess such effects by comparing 2 different drugs or treatment strategies. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b5093bad4f03d5e2736f4b4ce3f422a
https://doi.org/10.1161/hyp.64.suppl_1.506
https://doi.org/10.1161/hyp.64.suppl_1.506
Autor:
Andrés Navarro-Ruiz, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Pablo García-Pavía, Francisco Javier Martín Sánchez, Patricia Tarilonte, C. Peral, Francesc Formiga, Alejandra López-Ibáñez de Aldecoa
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
VALUE IN HEALTH
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Universidad de Barcelona
VALUE IN HEALTH
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Objective: To estimate the health and economic impact of the reduction in mortality and cardiovascular hospitalizations, associated with correct diagnosis of cardiac transthyretin amyloidosis (ATTR-CM), from the Spanish National Health System (NHS) p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad72177354950531920a87ebb164b53
http://hdl.handle.net/2445/178415
http://hdl.handle.net/2445/178415
